Hepatitis A Vaccines

Two New HAV Vaccines Available

Published in Hepatitis Weekly, March 23rd, 1998

Pharmaceutical companies Merck and Co. and SmithKline Beecham each have developed and now are marketing an inactivated hepatitis A vaccine.

According to an article in Obstetrics and Gynecology, both vaccines provide at-risk people over the age of two long-term protection against hepatitis A virus (HAV) infection (Duff and Duff, "Hepatitis A Vaccine: Ready for Prime Time," Obstet Gynecol, March 1998;91(3):468-471). Seroconversion rates exceed 95 percent.

The Merck vaccine goes by the brand name Vaqta. Administered intramuscularly, adults are recommended to receive 1.0 mL (50 U HAV antigen) and then a booster shot six to 12 months later; children...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1998-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry